MicroRNAs regulating apolipoprotein B-containing lipoprotein production

被引:15
|
作者
Zhou, Liye [1 ,2 ,3 ]
Irani, Sara [1 ,2 ,3 ]
Sirwi, Alaa [1 ,2 ,3 ]
Hussain, M. Mahmood [2 ,3 ,4 ]
机构
[1] Sch Grad Studies, Mol & Cell Biol Program, Brooklyn, NY USA
[2] Suny Downstate Med Ctr, Dept Cell Biol, 450 Clarkson Ave, Brooklyn, NY 11203 USA
[3] Suny Downstate Med Ctr, Dept Pediat, 450 Clarkson Ave, Brooklyn, NY 11203 USA
[4] VA New York Harbor Healthcare Syst, Brooklyn, NY USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2016年 / 1861卷 / 12期
基金
美国国家卫生研究院;
关键词
MicroRNA; Cholesterol; Triglyceride; Hyperlipidemia; Hepatosteatosis; Atherosclerosis; TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; NUCLEAR FACTOR 4-ALPHA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HEP G2 CELLS; APO-B; TRANSCRIPTIONAL REGULATION; STATIN INTOLERANCE; NONHUMAN-PRIMATES; PCSK9; INHIBITION;
D O I
10.1016/j.bbalip.2016.02.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MicroRNAs (miRs) are small, non-coding RNAs that regulate gene expression and have been implicated in many pathological conditions. Significant progress has been made to unveil their role in lipid metabolism. This review aims at summarizing the role of different miRs that regulate hepatic assembly and secretion of apolipoprotein B (apoB)-containing lipoproteins. Overproduction and/or impaired clearance of these lipoproteins from circulation increase plasma concentrations of lipids enhancing risk for cardiovascular disease. So far, three miRs, miR-122, miR-34a, and miR-30c have been shown to modulate hepatic production of apoB-containing low density lipoproteins. In this review, we will first provide a brief overview of lipid metabolism and apoB-containing lipoprotein assembly to orient readers to different steps that have been shown to be regulated by miRs. Then, we will discuss the role of each miR on plasma lipids and atherosclerotic burden. Furthermore, we will summarize mechanistic studies explaining how these miRs regulate hepatic lipid synthesis, fatty acid oxidation, and lipoprotein secretion. Finally, we will briefly highlight the potential use of each miR as a therapeutic drug for treating cardiovascular diseases. This article is part of a Special Issue entitled: MicroRNAs and lipid/energy metabolism and related diseases edited by Carlos Fernandez-Hernando and Yajaira Suarez. (C) 2016 Published by Elsevier B.V.
引用
收藏
页码:2062 / 2068
页数:7
相关论文
共 50 条
  • [31] Laboratory validation of a low density lipoprotein apolipoprotein-B assay
    Kelsey, David E.
    Toher, Jessica L.
    Foster, Michael T.
    Boulanger, James A.
    Cervinski, Mark A.
    CLINICAL BIOCHEMISTRY, 2014, 47 (16-17) : 211 - 215
  • [32] PLASMA-LIPOPROTEIN METABOLISM IN TRANSGENIC MICE OVEREXPRESSING APOLIPOPROTEIN-E - ACCELERATED CLEARANCE OF LIPOPROTEINS CONTAINING APOLIPOPROTEIN-B
    SHIMANO, H
    YAMADA, N
    KATSUKI, M
    YAMAMOTO, K
    GOTODA, T
    HARADA, K
    SHIMADA, M
    YAZAKI, Y
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (05) : 2084 - 2091
  • [33] Inflammatory NF-κB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production
    Tsai, Julie
    Zhang, Rianna
    Qiu, Wei
    Su, Qiaozhu
    Naples, Mark
    Adeli, Khosrow
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 296 (06): : G1287 - G1298
  • [34] RECENT ADVANCES IN LIPOPROTEIN AND ATHEROSCLEROSIS RESEARCH AT BAYLOR COLLEGE OF MEDICINE - APOLIPOPROTEIN-B, LIPOPROTEIN[A], AND TRANSPLANTATION ARTERIOPATHY
    BALLANTYNE, CM
    CHAN, L
    GUEVARA, J
    MORRISETT, JD
    MIMS, MP
    GOTTO, AM
    TEXAS HEART INSTITUTE JOURNAL, 1994, 21 (01) : 48 - 55
  • [35] Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins
    Lie, J
    de Crom, R
    van Gent, T
    van Haperen, R
    Scheek, L
    Sadeghi-Niaraki, F
    van Tol, A
    JOURNAL OF LIPID RESEARCH, 2004, 45 (05) : 805 - 811
  • [36] APOLIPOPROTEIN-A-I AND APOLIPOPROTEIN-B CONTAINING LIPOPROTEIN PARTICLES IN CORONARY PATIENTS TREATED WITH EXTRACORPOREAL LOW-DENSITY-LIPOPROTEIN PRECIPITATION (HELP)
    KOREN, E
    ARMSTRONG, VW
    MUELLER, G
    WILSON, PR
    SCHUFFWERNER, P
    THIERY, J
    EISENHAUER, T
    ALAUPOVIC, P
    SEIDEL, D
    ATHEROSCLEROSIS, 1992, 95 (2-3) : 157 - 170
  • [37] Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk
    Lai, Yuhui
    Zhang, Shaozhao
    Guo, Yue
    Xu, Chaoguang
    Huang, Mengting
    Zhan, Rongjian
    Liu, Menghui
    Xiong, Zhenyu
    Huang, Yiquan
    Liao, Xinxue
    Ma, Yuedong
    Zhuang, Xiaodong
    Jiang, Jingzhou
    Wu, Xing
    AMERICAN HEART JOURNAL, 2025, 281 : 157 - 167
  • [38] REFINING LIPOPROTEIN ASSESSMENT IN DIABETES: APOLIPOPROTEIN B MAKES SENSE
    Ganda, Om P.
    ENDOCRINE PRACTICE, 2009, 15 (04) : 370 - 376
  • [39] Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis
    Tomkin, GH
    Owens, D
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2001, 17 (01) : 27 - 43
  • [40] Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production
    Millar, JS
    Maugeais, C
    Ikewaki, K
    Kolansky, DM
    Barrett, PHR
    Budreck, EC
    Boston, RC
    Tada, N
    Mochizuki, S
    Defesche, JC
    Wilson, JM
    Rader, DJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (03) : 560 - 565